LUNG Company Profile and Key Details

Q: Who are the executives of LUNG?

Mr. David A. LehmanGen. Counsel & Sec.Ms. Lisa PaulChief People OfficerMr. Sri RadhakrishnanChief Technical OfficerMr. Geoffrey Beran RoseChief Commercial OfficerMs. Marcee M. MaroneyVice President of MarketingMr. Jérôme ErathSenior Vice President & GM of Europe Middle-East & AfricaSarah HuberVice President of Sales (U.S.)Dr. Derrick Sung Ph.D.Chief Financial OfficerMs. Lauren CristinaVice President of Fin. & Admin. (U.S.)Mr. Glendon E. FrenchChief Executive Officer, Pres & Director

NASDAQ : LUNG

Pulmonx

$1.63

0.02+1.24%

At Close 4:00 PM

56.79

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Pulmonx Corporation (LUNG) stock surged +1.24%, trading at $1.63 on NASDAQ, up from the previous close of $1.61. The stock opened at $1.59, fluctuating between $1.53 and $1.85 in the recent session.

Stock Snapshot

1.61

Prev. Close

68.85M

Market Cap

1.53

Day Low

-1.25

P/E Ratio

-1.3

EPS (TTM)

-1

Cash Flow per Share

1.59

Open

42.24M

Number of Shares

1.85

Day High

97.34%

Free Float in %

3.08

Book Value

1.68M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 31, 2026	1.60	1.85	1.51	1.63	1.68M
Jul 30, 2026	1.40	1.81	1.33	1.61	4.8M
Jul 29, 2026	1.27	1.28	1.22	1.25	210.45K
Jul 28, 2026	1.23	1.31	1.22	1.25	246.33K
Jul 27, 2026	1.18	1.26	1.18	1.22	247.36K
Jul 24, 2026	1.22	1.24	1.17	1.17	238.62K
Jul 23, 2026	1.21	1.23	1.17	1.22	281.82K
Jul 22, 2026	1.26	1.28	1.21	1.21	215.81K
Jul 21, 2026	1.34	1.35	1.21	1.27	413.96K
Jul 20, 2026	1.39	1.39	1.35	1.36	171.45K
Jul 17, 2026	1.42	1.48	1.36	1.40	108.32K
Jul 16, 2026	1.43	1.55	1.40	1.45	181.15K
Jul 15, 2026	1.48	1.51	1.43	1.44	112.14K
Jul 14, 2026	1.45	1.49	1.40	1.48	191.63K
Jul 13, 2026	1.54	1.61	1.44	1.46	269.85K
Jul 10, 2026	1.46	1.55	1.43	1.54	206.57K
Jul 09, 2026	1.46	1.48	1.42	1.47	228.26K
Jul 08, 2026	1.48	1.53	1.42	1.45	234.41K
Jul 07, 2026	1.47	1.55	1.44	1.53	204.27K
Jul 06, 2026	1.40	1.52	1.39	1.48	197.54K

Contact Details

Redwood City, CA 94063

United States

https://pulmonx.com 650 364 0400

About Company

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.

Stock Peers

ISRG

0.36+0.10%

Intuitive Surgical, Inc.$353.33 SWAV

-0.08-0.02%

ShockWave Medical, Inc.$334.75 UFPT

-0.25-0.10%

UFP Technologies, Inc.$254.78 MASI

Masimo Corporation$179.95 ALGN

-4.25-2.45%

Align Technology, Inc.$169.16 PODD

-0.33-0.20%

Insulet Corp.$165.35 IRTC

-1.91-1.60%

iRhythm Technologies, Inc.$117.17 ESTA

-0.94-1.01%

Establishment Labs Holdings Inc.$92.54 IRMD

-4.35-4.57%

IRadimed Corporation$90.86 DXCM

8.91+11.95%

DexCom, Inc.$83.45

Company Overview

Pulmonx Corporation (NASDAQ:LUNG) closed at $1.63 USD, gaining $0.02 (1.24%) from the previous close of $1.61. The stock is currently mid-range between its 52-week high and low $1.13 and $2.89. With a market capitalization of about $68.85 million, Pulmonx Corporation is classified as a micro-cap and shows lower-than-market volatility (beta ~0.31). Key stats such as the average daily volume over the past year has been around 511.55 thousand shares, trading with heavier-than-usual volume. Headquartered in Redwood City, CA, Pulmonx Corporation operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Glendon E. French, the company employs approximately 296 people and listed since October 01, 2020. Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 7.84%, SMA50 -13.11%, SMA200 -22.71%). The stock’s 14-day RSI is 51.38 (neutral), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -82.4% below its high and over 25.19% above its low. Average 10-day trading volume of 926.28 thousand shares is significantly above the 3-month average of 529.22 thousand, indicating heightened recent market interest.

Valuation Metrics

Pulmonx Corporation trades at a P/E ratio of -1.48, slightly below the S&P 500 average, with a price-to-sales ratio of 0.82 and a price-to-book ratio of 1.83 suggesting the stock is closer to book value. The P/FCF stands at -2.44, also above market averages.

Dividend & Fair Value

Pulmonx Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.07. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Pulmonx Corporation generated EPS of -$1.41 over the past year. Five-year average earnings growth is -19.8%. Wall Street analysts project EPS growth of 14.12% annually over the next five years. The latest quarter delivered EPS of -$0.24. The next quarter is forecast at -$0.39. Next year's EPS is expected at $3.52. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 11 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $2.50. The high target offers 881.6% upside. The low target suggests 53.37% downside. The mean target is $10.04. This offers 515.95% upside. Pulmonx Corporation earnings surprise history is frequent misses against expectations. The quarter that ended July 29, 2026, missed forecasts by -14.29%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -2.7% in April 30, 2025.

Shareholding & Insider Activity

Pulmonx Corporation has 42.24 million shares outstanding. The public float is 36.97 million shares, elevated short interest at 2.97% of float. This equals 1.06 million shares. The short ratio is 1.88 days. Institutional investors hold 82.69% of the float. Insiders own 4.89%. French Glendon E. III holds 1.41 million shares, Sung Derrick has 391.04 thousand shares and Rose Geoffrey Beran has 365.73 thousand shares. Over the past six months, insider transactions show net selling. They sold 69.53 thousand shares across 4 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Pulmonx generated $68.68M in revenue, or $1.81 per share. Gross margin was 73.32%, operating margin -90.19%, and net profit margin -88.60%. Returns are negative, with ROA at -34.00% and ROE at -51.42%.
On valuation metrics, Pulmonx trades at a P/E of -1.48, P/S of 0.82 and P/B of 1.83. The current ratio is 4.32 and quick ratio is 3.52. Operationally, the company’s inventory turnover is 1.22 and cash conversion cycle is 264.25 days. Debt-to-equity is 1.43, supported by a cash flow-to-debt ratio of -0.52.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Pulmonx posted revenue of $68.68M, down slightly from $53.66M in the prior quarter. Gross profit was $50.35M (margin 73.32%). Operating income was - $61.94M (margin -90.2%). Net income was- $60.84M (EPS - $1.60).
The company ended the quarter with $117.34M in cash and short-term investments, a total debt of $41.42M, and net debt of - $42.36M. Total assets were $178.95M, with equity of $118.32M. Financials further reflected weakness, with operating cash flow of - $37.61M, free cash flow of - $38.42M, and capital expenditures of - $807.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Pulmonx Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.5%, with price expected at $1.41 by August 13, 2026, within a range of $1.28 to $1.55 3-Month Outlook: Projected fall of -27.61%, reaching $1.18 by October 28, 2026, with a range of $0.93 to $1.34. 1-Year Outlook: Projected gain of 27.61%, with price at $2.08 by July 30, 2027, within a range of $0.00 to $0.00.

Key Takeaways

Pulmonx Corporation (NASDAQ:LUNG) shares are down -19.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Pulmonx Corporation trading at a premium to the broader market with a P/E of -1.48. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.53, suggesting 975.46% upside. Our AI forecast model points to short-term weakness (-13.5% over two weeks), a medium-term fall (-27.61% over three months), and a longer-term gain (27.61% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Pulmonx Corporation (LUNG) stock price?

Pulmonx Corporation (NASDAQ: LUNG) stock price is $1.63 in the last trading session. During the trading session, LUNG stock reached the peak price of $1.85 while $1.53 was the lowest point it dropped to. The percentage change in LUNG stock occurred in the recent session was 1.24% while the dollar amount for the price change in LUNG stock was $0.02.

LUNG's industry and sector of operation?

The NASDAQ listed LUNG is part of Medical - Devices industry that operates in the broader Healthcare sector. Pulmonx Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of LUNG?

Mr. David A. Lehman
Gen. Counsel & Sec.
Ms. Lisa Paul
Chief People Officer
Mr. Sri Radhakrishnan
Chief Technical Officer
Mr. Geoffrey Beran Rose
Chief Commercial Officer
Ms. Marcee M. Maroney
Vice President of Marketing
Mr. Jérôme Erath
Senior Vice President & GM of Europe Middle-East & Africa
Sarah Huber
Vice President of Sales (U.S.)
Dr. Derrick Sung Ph.D.
Chief Financial Officer
Ms. Lauren Cristina
Vice President of Fin. & Admin. (U.S.)
Mr. Glendon E. French
Chief Executive Officer, Pres & Director

How LUNG did perform over past 52-week?

LUNG's closing price is 44.25% higher than its 52-week low of $1.13 where as its distance from 52-week high of $2.89 is -43.6%.

How many employees does LUNG have?

Number of LUNG employees currently stands at 296.

Link for LUNG official website?

Official Website of LUNG is: https://pulmonx.com

How do I contact LUNG?

LUNG could be contacted at phone 650 364 0400 and can also be accessed through its website. LUNG operates from 700 Chesapeake Drive, Redwood City, CA 94063, United States.

How many shares of LUNG are traded daily?

LUNG stock volume for the day was 1.68M shares. The average number of LUNG shares traded daily for last 3 months was 511.55K.

What is the market cap of LUNG currently?

The market value of LUNG currently stands at $68.85M with its latest stock price at $1.63 and 42.24M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	296
Beta	0.31
Sales or Revenue	$68.68M
5Y Sales Change%	0.872%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Devices

LUNG Company Profile and Key Details

Pulmonx

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways